Price Alert: Shares of NeuBase (NBSE) Trade 7.12% Higher at Midday June 21

Equities Staff  |

NeuBase Therapeutics Inc (NASDAQ: NBSE) has gained $0.0598 (7.12%) and sits at $0.90, as of 11:08:24 est on June 21.

28,258 shares have traded hands.

The Company fell 12.63% over the last 5 days and shares fell 16.00% over the last 30 days.

NeuBase anticipates its next earnings on 2022-08-11.

For technical charts, analysis, and more on NeuBase visit the company profile.

About NeuBase Therapeutics Inc

NeuBase Therapeutics Inc. is accelerating the genetic revolution using a new class of synthetic medicines which have been shown to be able to increase, decrease and change gene function, as appropriate, to resolve causal genetic defects in living systems. NeuBase's designer PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions.

To get more information on NeuBase Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: NeuBase Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade
What You Need To Know About Bear Markets
Is Your iPhone Already Obsolete?



Market Movers

Sponsored Financial Content